Annual CFF
$32.48 M
-$55.54 M-63.10%
31 December 2023
Summary:
BioCryst Pharmaceuticals annual cash flow from financing activities is currently $32.48 million, with the most recent change of -$55.54 million (-63.10%) on 31 December 2023. During the last 3 years, it has fallen by -$268.10 million (-89.19%). BCRX annual CFF is now -90.97% below its all-time high of $359.67 million, reached on 31 December 2021.BCRX Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$1.27 M
+$3.24 M+164.80%
30 September 2024
Summary:
BioCryst Pharmaceuticals quarterly cash flow from financing activities is currently $1.27 million, with the most recent change of +$3.24 million (+164.80%) on 30 September 2024. Over the past year, it has increased by +$49.00 thousand (+4.00%). BCRX quarterly CFF is now -99.63% below its all-time high of $347.42 million, reached on 31 December 2021.BCRX Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
-$4.91 M
+$49.00 K+0.99%
30 September 2024
Summary:
BioCryst Pharmaceuticals TTM cash flow from financing activities is currently -$4.91 million, with the most recent change of +$49.00 thousand (+0.99%) on 30 September 2024. Over the past year, it has dropped by -$44.77 million (-112.33%). BCRX TTM CFF is now -101.14% below its all-time high of $431.25 million, reached on 30 September 2022.BCRX TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BCRX Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -63.1% | +4.0% | -112.3% |
| 3 y3 years | -89.2% | -73.3% | -102.3% |
| 5 y5 years | -48.0% | +592.4% | -122.4% |
BCRX Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -91.0% | at low | -99.6% | +140.2% | -101.1% | +1.0% |
| 5 y | 5 years | -91.0% | at low | -99.6% | +127.5% | -101.1% | +1.0% |
| alltime | all time | -91.0% | >+9999.0% | -99.6% | +127.5% | -101.1% | +1.0% |
BioCryst Pharmaceuticals Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $1.27 M(-164.8%) | -$4.91 M(-1.0%) |
| June 2024 | - | -$1.97 M(+87.6%) | -$4.96 M(-118.8%) |
| Mar 2024 | - | -$1.05 M(-67.0%) | $26.36 M(-18.9%) |
| Dec 2023 | $32.48 M(-63.1%) | -$3.17 M(-359.0%) | $32.48 M(-18.5%) |
| Sept 2023 | - | $1.23 M(-95.8%) | $39.86 M(-65.3%) |
| June 2023 | - | $29.36 M(+478.2%) | $114.96 M(+34.1%) |
| Mar 2023 | - | $5.08 M(+20.9%) | $85.75 M(-2.6%) |
| Dec 2022 | $88.03 M(-75.5%) | $4.20 M(-94.5%) | $88.03 M(-79.6%) |
| Sept 2022 | - | $76.33 M(>+9900.0%) | $431.25 M(+19.9%) |
| June 2022 | - | $147.00 K(-98.0%) | $359.70 M(-1.2%) |
| Mar 2022 | - | $7.36 M(-97.9%) | $364.12 M(+1.2%) |
| Dec 2021 | $359.67 M(+19.7%) | $347.42 M(+7174.2%) | $359.67 M(+72.1%) |
| Sept 2021 | - | $4.78 M(+4.4%) | $209.01 M(+4.7%) |
| June 2021 | - | $4.57 M(+57.7%) | $199.60 M(-34.2%) |
| Mar 2021 | - | $2.90 M(-98.5%) | $303.22 M(+0.9%) |
| Dec 2020 | $300.59 M(+203.3%) | $196.76 M(-4346.0%) | $300.59 M(+64.9%) |
| Sept 2020 | - | -$4.63 M(-104.3%) | $182.29 M(-2.6%) |
| June 2020 | - | $108.20 M(>+9900.0%) | $187.11 M(+135.9%) |
| Mar 2020 | - | $266.00 K(-99.7%) | $79.32 M(-20.0%) |
| Dec 2019 | $99.10 M(+58.5%) | $78.46 M(>+9900.0%) | $99.10 M(+351.0%) |
| Sept 2019 | - | $184.00 K(-55.6%) | $21.98 M(-74.4%) |
| June 2019 | - | $414.00 K(-97.9%) | $85.71 M(+2.0%) |
| Mar 2019 | - | $20.04 M(+1398.9%) | $84.02 M(+34.4%) |
| Dec 2018 | $62.50 M(-53.9%) | $1.34 M(-97.9%) | $62.50 M(+1.2%) |
| Sept 2018 | - | $63.92 M(-5113.2%) | $61.74 M(-26.6%) |
| June 2018 | - | -$1.27 M(-13.6%) | $84.13 M(-1.6%) |
| Mar 2018 | - | -$1.48 M(-357.6%) | $85.53 M(-37.0%) |
| Dec 2017 | $135.70 M(+482.3%) | $573.00 K(-99.3%) | $135.70 M(-1.3%) |
| Sept 2017 | - | $86.31 M(>+9900.0%) | $137.46 M(+87.1%) |
| June 2017 | - | $118.00 K(-99.8%) | $73.48 M(+2.3%) |
| Mar 2017 | - | $48.70 M(+1988.3%) | $71.87 M(+208.4%) |
| Dec 2016 | $23.30 M(+325.3%) | $2.33 M(-89.6%) | $23.30 M(+10.7%) |
| Sept 2016 | - | $22.34 M(-1588.0%) | $21.06 M(-3448.0%) |
| June 2016 | - | -$1.50 M(-1187.7%) | -$629.00 K(-115.3%) |
| Mar 2016 | - | $138.00 K(+58.6%) | $4.12 M(-24.9%) |
| Dec 2015 | $5.48 M(-95.1%) | $87.00 K(-86.6%) | $5.48 M(-4.8%) |
| Sept 2015 | - | $647.00 K(-80.1%) | $5.75 M(-32.2%) |
| June 2015 | - | $3.24 M(+116.1%) | $8.48 M(-92.4%) |
| Mar 2015 | - | $1.50 M(+315.8%) | $111.01 M(-0.8%) |
| Dec 2014 | $111.91 M(+269.7%) | $361.00 K(-89.3%) | $111.91 M(-1.3%) |
| Sept 2014 | - | $3.37 M(-96.8%) | $113.44 M(-12.8%) |
| June 2014 | - | $105.77 M(+4303.5%) | $130.08 M(+339.0%) |
| Mar 2014 | - | $2.40 M(+27.0%) | $29.63 M(-2.1%) |
| Dec 2013 | $30.27 M(+78.5%) | $1.89 M(-90.6%) | $30.27 M(+5.5%) |
| Sept 2013 | - | $20.01 M(+275.8%) | $28.70 M(+165.3%) |
| June 2013 | - | $5.33 M(+75.2%) | $10.82 M(+34.0%) |
| Mar 2013 | - | $3.04 M(+862.0%) | $8.07 M(-52.4%) |
| Dec 2012 | $16.96 M(-28.6%) | $316.00 K(-85.2%) | $16.96 M(-2.1%) |
| Sept 2012 | - | $2.14 M(-17.2%) | $17.32 M(+17.5%) |
| June 2012 | - | $2.58 M(-78.3%) | $14.75 M(+29.5%) |
| Mar 2012 | - | $11.93 M(+1656.3%) | $11.39 M(-52.0%) |
| Dec 2011 | $23.75 M(+2758.6%) | $679.00 K(-254.7%) | $23.75 M(+2.3%) |
| Sept 2011 | - | -$439.00 K(-43.2%) | $23.22 M(-2.4%) |
| June 2011 | - | -$773.00 K(-103.2%) | $23.78 M(-4.0%) |
| Mar 2011 | - | $24.29 M(>+9900.0%) | $24.77 M(+2880.9%) |
| Dec 2010 | $831.00 K(-98.3%) | $145.00 K(+19.8%) | $831.00 K(-98.2%) |
| Sept 2010 | - | $121.00 K(-44.2%) | $46.98 M(-2.9%) |
| June 2010 | - | $217.00 K(-37.6%) | $48.36 M(+0.4%) |
| Mar 2010 | - | $348.00 K(-99.2%) | $48.15 M(+0.5%) |
| Dec 2009 | $47.90 M | $46.29 M(+2981.9%) | $47.90 M(+2835.5%) |
| Sept 2009 | - | $1.50 M(>+9900.0%) | $1.63 M(+452.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2009 | - | $14.00 K(-84.4%) | $295.60 K(+5.0%) |
| Mar 2009 | - | $90.00 K(+251.6%) | $281.60 K(-57.8%) |
| Dec 2008 | $666.60 K(-99.0%) | $25.60 K(-84.6%) | $666.60 K(-1.1%) |
| Sept 2008 | - | $166.00 K(>+9900.0%) | $673.90 K(-99.0%) |
| June 2008 | - | $0.00(-100.0%) | $66.04 M(-1.4%) |
| Mar 2008 | - | $475.00 K(+1343.8%) | $66.95 M(+0.3%) |
| Dec 2007 | $66.77 M(+2154.8%) | $32.90 K(-99.9%) | $66.77 M(-0.1%) |
| Sept 2007 | - | $65.53 M(+7109.4%) | $66.84 M(+4566.9%) |
| June 2007 | - | $909.00 K(+209.2%) | $1.43 M(+41.4%) |
| Mar 2007 | - | $294.00 K(+184.9%) | $1.01 M(-65.8%) |
| Dec 2006 | $2.96 M(-94.6%) | $103.20 K(-18.1%) | $2.96 M(-91.3%) |
| Sept 2006 | - | $126.00 K(-74.3%) | $34.05 M(-3.0%) |
| June 2006 | - | $490.00 K(-78.1%) | $35.10 M(+1.4%) |
| Mar 2006 | - | $2.24 M(-92.8%) | $34.61 M(-37.3%) |
| Dec 2005 | $55.18 M(+156.9%) | $31.19 M(+2543.1%) | $55.18 M(+128.8%) |
| Sept 2005 | - | $1.18 M(>+9900.0%) | $24.11 M(+4.3%) |
| June 2005 | - | $0.00(-100.0%) | $23.13 M(-3.1%) |
| Mar 2005 | - | $22.81 M(>+9900.0%) | $23.86 M(+11.1%) |
| Dec 2004 | $21.48 M(+2287.3%) | $122.80 K(-36.4%) | $21.48 M(-3.3%) |
| Sept 2004 | - | $193.00 K(-73.7%) | $22.22 M(+0.7%) |
| June 2004 | - | $733.00 K(-96.4%) | $22.06 M(+3.4%) |
| Mar 2004 | - | $20.43 M(+2273.6%) | $21.32 M(+2270.1%) |
| Dec 2003 | $899.70 K(+633.8%) | $860.70 K(+2508.2%) | $899.70 K(+2230.8%) |
| Sept 2003 | - | $33.00 K(>+9900.0%) | $38.60 K(+39.9%) |
| June 2003 | - | $0.00(-100.0%) | $27.60 K(0.0%) |
| Mar 2003 | - | $6000.00(-1600.0%) | $27.60 K(-77.5%) |
| Dec 2002 | $122.60 K(-34.1%) | -$400.00(-101.8%) | $122.60 K(-19.9%) |
| Sept 2002 | - | $22.00 K(>+9900.0%) | $153.00 K(-45.0%) |
| June 2002 | - | $0.00(-100.0%) | $278.00 K(+1.5%) |
| Mar 2002 | - | $101.00 K(+236.7%) | $274.00 K(+47.3%) |
| Dec 2001 | $186.00 K(-87.9%) | $30.00 K(-79.6%) | $186.00 K(-28.0%) |
| Sept 2001 | - | $147.00 K(-3775.0%) | $258.40 K(-17.0%) |
| June 2001 | - | -$4000.00(-130.8%) | $311.40 K(-49.0%) |
| Mar 2001 | - | $13.00 K(-87.3%) | $610.40 K(-60.3%) |
| Dec 2000 | $1.54 M(-96.9%) | $102.40 K(-48.8%) | $1.54 M(-96.8%) |
| Sept 2000 | - | $200.00 K(-32.2%) | $48.44 M(-3.4%) |
| June 2000 | - | $295.00 K(-68.7%) | $50.14 M(+0.6%) |
| Mar 2000 | - | $941.00 K(-98.0%) | $49.84 M(+1.7%) |
| Dec 1999 | $49.00 M(+610.1%) | $47.00 M(+2373.7%) | $49.00 M(+490.4%) |
| Sept 1999 | - | $1.90 M(>+9900.0%) | $8.30 M(+27.7%) |
| June 1999 | - | $0.00(-100.0%) | $6.50 M(0.0%) |
| Mar 1999 | - | $100.00 K(-98.4%) | $6.50 M(-5.8%) |
| Dec 1998 | $6.90 M(+3350.0%) | $6.30 M(+6200.0%) | $6.90 M(+1050.0%) |
| Sept 1998 | - | $100.00 K(>+9900.0%) | $600.00 K(0.0%) |
| June 1998 | - | $0.00(-100.0%) | $600.00 K(+20.0%) |
| Mar 1998 | - | $500.00 K(>+9900.0%) | $500.00 K(+150.0%) |
| Dec 1997 | $200.00 K(-99.4%) | $0.00(-100.0%) | $200.00 K(-99.1%) |
| Sept 1997 | - | $100.00 K(-200.0%) | $22.60 M(+2.3%) |
| June 1997 | - | -$100.00 K(-150.0%) | $22.10 M(-6.8%) |
| Mar 1997 | - | $200.00 K(-99.1%) | $23.70 M(-24.8%) |
| Dec 1996 | $31.50 M(+275.0%) | $22.40 M(-5700.0%) | $31.50 M(+250.0%) |
| Sept 1996 | - | -$400.00 K(-126.7%) | $9.00 M(-4.3%) |
| June 1996 | - | $1.50 M(-81.3%) | $9.40 M(-43.0%) |
| Mar 1996 | - | $8.00 M(-8100.0%) | $16.50 M(+96.4%) |
| Dec 1995 | $8.40 M(-43.6%) | -$100.00 K(<-9900.0%) | $8.40 M(0.0%) |
| Sept 1995 | - | $0.00(-100.0%) | $8.40 M(-18.4%) |
| June 1995 | - | $8.60 M(-8700.0%) | $10.30 M(+543.8%) |
| Mar 1995 | - | -$100.00 K(0.0%) | $1.60 M(-89.3%) |
| Dec 1994 | $14.90 M | -$100.00 K(-105.3%) | $14.90 M(-0.7%) |
| Sept 1994 | - | $1.90 M(-2000.0%) | $15.00 M(+14.5%) |
| June 1994 | - | -$100.00 K(-100.8%) | $13.10 M(-0.8%) |
| Mar 1994 | - | $13.20 M | $13.20 M |
FAQ
- What is BioCryst Pharmaceuticals annual cash flow from financing activities?
- What is the all time high annual CFF for BioCryst Pharmaceuticals?
- What is BioCryst Pharmaceuticals annual CFF year-on-year change?
- What is BioCryst Pharmaceuticals quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for BioCryst Pharmaceuticals?
- What is BioCryst Pharmaceuticals quarterly CFF year-on-year change?
- What is BioCryst Pharmaceuticals TTM cash flow from financing activities?
- What is the all time high TTM CFF for BioCryst Pharmaceuticals?
- What is BioCryst Pharmaceuticals TTM CFF year-on-year change?
What is BioCryst Pharmaceuticals annual cash flow from financing activities?
The current annual CFF of BCRX is $32.48 M
What is the all time high annual CFF for BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals all-time high annual cash flow from financing activities is $359.67 M
What is BioCryst Pharmaceuticals annual CFF year-on-year change?
Over the past year, BCRX annual cash flow from financing activities has changed by -$55.54 M (-63.10%)
What is BioCryst Pharmaceuticals quarterly cash flow from financing activities?
The current quarterly CFF of BCRX is $1.27 M
What is the all time high quarterly CFF for BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals all-time high quarterly cash flow from financing activities is $347.42 M
What is BioCryst Pharmaceuticals quarterly CFF year-on-year change?
Over the past year, BCRX quarterly cash flow from financing activities has changed by +$49.00 K (+4.00%)
What is BioCryst Pharmaceuticals TTM cash flow from financing activities?
The current TTM CFF of BCRX is -$4.91 M
What is the all time high TTM CFF for BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals all-time high TTM cash flow from financing activities is $431.25 M
What is BioCryst Pharmaceuticals TTM CFF year-on-year change?
Over the past year, BCRX TTM cash flow from financing activities has changed by -$44.77 M (-112.33%)